Telix Pharmaceuticals Limited reported group revenue of US$247 million for the quarter ended June 30, 2026 (Q2 2026), representing a 21% increase year-over-year and a 7% rise quarter-over-quarter. The company anticipates FY 2026 revenue and other income will exceed US$1 billion, with revenue tracking in line with the upper end of its guidance range of US$950 million to US$970 million, plus US$40 million in non-refundable other income received from Regeneron. Precision Medicine revenue drove the growth, reaching US$202 million, up 30% year-over-year.

Financial Performance

The strong commercial performance enabled Telix to update its FY 2026 research and development expenditure guidance to a range of US$230 million to US$270 million. This increase is supported by the US$40 million non-refundable payment from Regeneron and aims to accelerate high-value clinical programs. Telix Manufacturing Solutions (TMS) revenue for the quarter was US$45 million.

Operational and Strategic Milestones

Telix achieved key regulatory advancements, including alignment with the United States Food and Drug Administration (FDA) for the ProstACT Global Phase 3 study of TLX591-Tx to advance to Part 2 in the U.S. The company also progressed its strategic collaboration with Regeneron to jointly develop and commercialize next-generation radiopharmaceutical therapies, initially focused on lung cancer. Additionally, Telix completed a refinancing of its convertible bond structure, issuing US$600 million of new convertible bonds due 2031 and repurchasing all outstanding 2029 convertible bonds.

Corporate Governance

Three new Non-Executive Directors were appointed to the Board effective May 11, 2026. David Gill, Maria Rivas, MD, and William Jellison joined the Board, enhancing the company's clinical, commercial, financial, and governance expertise.

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) has dosed the first patient with TLX250-Tx (lutetium-177 (177Lu) girentuximab tetraxetan) in its Phase 3 LUTEON study for relapsed or recurrent clear cell renal cell carcinoma (ccRCC). This marks the first radiopharmaceutical therapy to enter Phase 3 development for ccRCC, a significant milestone in targeted treatments for this aggressive cancer subtype. The study aims to address the poor outcomes for patients with relapsed or recurrent ccRCC, despite advances in care.

The patient was dosed at GenesisCare Murdoch in Western Australia under the supervision of Dr. Aviral Singh, Clinical Head of Theranostics and Nuclear Medicine at GenesisCare Murdoch and Principal Investigator on the LUTEON trial. Dr. David N. Cade, Telix Group Chief Medical Officer, highlighted that LUTEON represents the next stage in Telix’s global clinical development of TLX250-Tx.

TLX250-Tx is a first-in-class CAIX-targeting radio antibody-drug conjugate (rADC) therapy candidate composed of a high-specificity monoclonal antibody chelated to the therapeutic radionuclide lutetium-177. CAIX is expressed in more than 95% of ccRCC cases, with limited expression in normal tissues, making it an attractive therapeutic target.

The LUTEON study is a randomized, prospective, open-label, multi-center trial being conducted under a Phase 3 protocol in Australia. It forms part of Telix’s global development program for TLX250-Tx, which includes the separate Phase 2a LUTEON ATLAS study in the United States and Europe. The study utilizes Telix’s investigational PET imaging agent, TLX250-Px (Zircaix), to identify eligible patients with CAIX-positive tumors.

Clear cell renal cell carcinoma (ccRCC) is the most common and aggressive subtype of kidney cancer, representing about 85% of all renal cell carcinoma (RCC) cases. Up to 30% of patients present with metastatic disease at diagnosis, which has a 20% five-year survival rate. Telix’s commercial franchise is anchored by its prostate cancer imaging portfolio, Illuccix and Gozellix, while its late-stage therapeutic pipeline includes three assets in pivotal-stage trials, including TLX250-Tx for kidney cancer.